Twinvir ™ - combined antiviral agent.
One Twinvir ™ tablet contains Ladipasvir 90 mg and Sophosbuvir 400 mg.
The combination of Ledipasvir and Sofosbuvir is used for the treatment of hepatitis C of genotype 1, 4, 5 and 6 in adults.
28 tablets, film-coated.
Recommended dosage: one tablet (Ladipasvir 90 mg and Sofosbuvir 400 mg) is taken orally once a day. Recommended duration of treatment for patients without experience of negative response to therapy: 12 weeks. With experience of a negative response to therapy (without cirrhosis of the liver): 24 weeks. With experience of a negative response to therapy (with cirrhosis of the liver): 24 weeks.
Joint use of the drug with amiodarone can lead to bradycardia. P-gp inductors (rifampicin, rifabutin, St. John's wort, carbmazepine, phenobarbital and phenytoin) lower the concentration of Ladipasvir and Sofosbuvir in the blood, which adversely affects the effectiveness of treatment.
There is no data on the effect of the drug on fetal development and lactation. During pregnancy and breastfeeding, the drug can be prescribed only by the therapist.
The safety and efficacy of the combination of Ledipasvir and Sofosbuvir in patients under 18 years of age have not been studied.
Twinvir ™ is available in the form of tablets for oral administration. The composition includes two active components: Ladipasvir, which is an inhibitor of the viral protein, and also Sofosbuvir, an inhibitor of the RNA polymerase.
Bradycardia can occur in patients taking amiodarone, especially those who simultaneously use amiodarone with other drugs that slow the heart rate. The joint administration of amiodarone with the combination of Ledipasvir and Sofosbuvirais not recommended. Cardiac monitoring is recommended in patients without alternative treatment options. The dosage for patients with severe renal failure or renal insufficiency of the final stage is calculated individually by the attending physician. The use of Twinvir ™ with other drugs containing Sofosbuvir is not recommended.
Call is free
or enter your phone and we will call you back
Incepta Pharmaceuticals is a leading pharmaceutical company that was founded in 1999 in Bangladesh. We have large enterprises for the production of new drugs that are located in the territory of Savara and Dhamrai, located 35 and 53 kilometers from the center of the capital of Dhaka.
We produce and issue almost all kinds of dosage forms: tablets, capsules, oral liquids, ampoules, bottles with dry powders, nasal sprays, suspension powders, eye drops, creams, ointments, lotions, gels, pre-filled syringes, lyophilized injections, vaccines etc.
Since the foundation of our company, many new innovative products have been produced to meet the medical needs of the world community. The most important for us is the introduction of modern advanced technologies in medicine, their effectiveness and further development.
The main direction of Incepta Pharmaceuticals is the production and supply of high-tech and effective medicines. In our assortment there are the following kinds of dosage forms: sustained release tablets, quick dissolution tablets and effervescent tablets, sustained-release capsules, pre-filled syringes, insulin and its analogs, biological products and much more.
On the territory of our enterprise we have modern pharmaceutical laboratory for research and development of the latest drugs, including inhalers with dry powder, pellets with coating, products with assisted release, medicines with disguised taste, etc.
Our experienced sales staff successfully promote pharmaceutical products throughout the country. We also develop supplies to villages and urban areas of Bangladesh. The company covers virtually every single corner of the countryside, including the urban areas of Bangladesh. Incepta Pharmaceuticals has created its own large distribution network, consisting of 21 warehouses throughout the country.
Thanks to the developed strategy of our entry to the level of the leading research company for the production of dosage forms, Incepta Pharmaceuticals is successfully expanding its pharmaceutical activities. At present, we are supplying medicines of our own production to more than 60 different countries of the world. Thanks to hundreds of registered brands and the company's latest products under development, we are gradually strengthening our positions throughout all the continents.
The modern research laboratory of R&D company uses sophisticated advanced technologies to create new effective formulas based on studies previously unknown. Such activities not only benefit our company, but also the entire pharmaceutical sector. Soon we plan to officially launch the production of Active Pharmaceutical Ingredient (API).
In June 2011, Incepta Vaccines Limited, the subsidiary of Incepta Pharmaceuticals, established a modern enterprise in the Bangladesh market for the production and issue of vaccines for humans. Incepta is the first Bangladeshi company that acquired technology to create this kind of vaccine. Thanks to mass production, the company will be able to supply this product all over the world.
On January 15, 2011 Incepta introduced the world-famous ERP-SAP software system. Thus, we became the first Bangladeshi company to implement SAP for the management of medicinal resources. This system brought our daily activities to a new level, which allowed us to become more efficient in the production of drugs.
The company is constantly expanding its activities beyond the geographical boundaries of Bangladesh. We are open for cooperation with stakeholders in different countries. Incepta will continue to strive to provide high-quality medicine at affordable prices in Bangladesh and other parts of the world.
QMS is designed to describe our activities in practice and in various documents. This system is based on the main principles of PIC/S and WHO. The company's charter describes the quality policy of Incepta Pharmaceuticals.
Technical responsibility is borne by the management department, which covers all activities necessary to create, maintain and verify the quality of our medicines.
Quality control of the Zirabo plant is carried out by qualified employees who have passed certification. Their main tasks and responsibilities are described in the quality manual and the corresponding SOP. The head of the control service, as well as his delegates are responsible for the release of medicinal substances, their form and packaging materials.
The quality department is responsible for IPC, compliance with GMP and training of personnel. Periodically, the control of compliance with all the standards at the workplace is carried out by analyzing the manufactured batch of the drug and inspecting the workplaces for contamination. The production lines and parameters of the equipment used are checked.
The immediate duty of our employees of the quality control department is to conduct external and internal audits among the staff, with subsequent monitoring of the effectiveness of the processes.
The research department is responsible for developing the formulation and new methods of treatment. The main task performed by the department is the systematic analysis and quality control of the products.
The charter of Incepta Pharmaceuticals company describes the instructions for production testing, the implementation, which is mandatory for maintaining a stable output of quality products.
Our company regularly conducts independent inspections for safety checks, compliance with hygiene standards and compliance with GMP, including documentation.
The supply of raw materials is carried out by approved and verified suppliers. Their selection takes place through evaluation and agreement, in accordance with rules and procedures from the charter. The same rules apply to the supply of primary and secondary packaging materials.
Our team of quality control specialists, along with other relevant functions, is responsible for coordinating activities in all areas. Also, this department is responsible for bringing the changes made to the charter to the attention of all the parties involved.
The employees of the quality control department are responsible for the documentation, constant support and maintenance of all changes made to the charter.
The ventilation and air conditioning system serving the production and service areas is designed in accordance with the International Standard and meets all safety standards.
The company's charter contains the facility inspection plan. It describes the strategy covering the compliance of equipment with technical standards, production process and product quality checks, cleaning validation, personnel check, etc.
Staff training is a standard procedure in our company. The need for advanced training depends on the functions of the employee. Human Resources Department and a specialized group of inspectors reveals the expediency in training.
All the production stages are carried out according to the European quality standards by R&D on their own equipment.
The warehouses on which Incepta Pharmaceuticals products are stored have a GDP certificate.
Transportation is carried out with observance of all the temperature mode rules and standards.
Ordering a course of treatment with us, you get the original drug only.